---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-182695"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T12:17:36.377851+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ResMed elects AbbVie's Nicole Mowad-Nassar to board; director Sulpizio to retire in Nov 2025

## Summary
- Nicole Mowad-Nassar elected to ResMed board effective Aug 15, 2025; she is SVP at AbbVie and President of Specialty & U.S. Therapeutics Operations.
- She will serve on the Compensation and Leadership Development Committee; term expires at 2025 annual meeting on Nov 19, 2025.
- Director Richard Sulpizio to retire after 20 years, not standing for reelection at Nov 19 meeting; no disagreement with company.
- Sulpizio previously chaired Compensation, Audit, and Nominating & Governance committees during his tenure.

## SEC filing metadata
- accession: 0001193125-25-182695
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312525182695/0001193125-25-182695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312525182695/d72598d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-182695
- JSON: https://secwatch.observer/filing/0001193125-25-182695.json
- Plain text: https://secwatch.observer/filing/0001193125-25-182695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.